Use of antipsychotic polypharmacy among patients with schizophrenia and risk of death

被引：0
|
作者：
Gasse, Christiane [1 ]
Baandrup, Lone [2 ]
Nordentoft, Merete [4 ]
Glenthoj, Birte Y. [2 ]
Lublin, Henrik [2 ]
Jensen, Vibeke Dahl [3 ]
Thomsen, Lars Krogsgaard [3 ]
Poulsen, Jan [3 ]
Mortensen, Preben B. [1 ]
机构：
[1] Univ Aarhus, Natl Ctr Register Based Res, Aarhus, Denmark
[2] Copenhagen Univ Hosp, Fac Hlth Sci, Ctr Neuropsychiat Schizophrenia Res, Glostrup, Denmark
[3] Danish Med Agcy, Copenhagen, Denmark
[4] Copenhagen Univ Hosp, Dept Psychiat, Bispebjerg, Denmark
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2008年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
465
引用
收藏
页码：S204 / S205
页数：2
相关论文
共 50 条
  • [41] Effects of switching polypharmacy into antipsychotic monotherapy using perospirone in patients with schizophrenia
    Shimizu, Hideaki
    Hokoishi, Kazuhiko
    Fukuhara, Ryuji
    Ishikawa, Tomohisa
    Ikeda, Manabu
    Tanabe, Hirotaka
    [J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2007, 22 (05) : A5 - A5
  • [42] Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia
    Tiihonen, Jari
    Taipale, Heidi
    Mehtala, Juha
    Vattulainen, Pia
    Correll, Christoph U.
    Tanskanen, Antti
    [J]. JAMA PSYCHIATRY, 2019, 76 (05) : 499 - 507
  • [43] THE FREQUENCY OF ANTIPSYCHOTIC POLYPHARMACY IN "HIGH-UTILIZING'' PATIENTS WITH SCHIZOPHRENIA IN GERMANY
    Janssen, Birgit
    Schmidt-Kraepelin, C.
    Puschner, B.
    Gaebel, Wolfgang
    [J]. SCHIZOPHRENIA BULLETIN, 2011, 37 : 306 - 307
  • [44] Antipsychotic polypharmacy in treatment-resistant schizophrenia
    Dugan, DJ
    Vertrees, JE
    Saklad, SR
    Richards, AM
    Ereshefsky, L
    [J]. SCHIZOPHRENIA RESEARCH, 1999, 36 (1-3) : 278 - 278
  • [45] Recent trends in antipsychotic polypharmacy in the treatment of schizophrenia
    Yasui-Furukori, Norio
    Shimoda, Kazutaka
    [J]. NEUROPSYCHOPHARMACOLOGY REPORTS, 2020, 40 (03) : 208 - 210
  • [46] Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations
    Lahteenvuo, Markku
    Tiihonen, Jari
    [J]. DRUGS, 2021, 81 (11) : 1273 - 1284
  • [47] Antipsychotic polypharmacy in schizophrenia: evolving evidence and rationale
    Azorin, Jean-Michel
    Simon, Nicolas
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2020, 16 (12) : 1175 - 1186
  • [48] Critical review of antipsychotic polypharmacy in the treatment of schizophrenia
    Fleischhacker, W. Wolfgang
    Uchida, Hiroyuki
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2014, 17 (07): : 1083 - 1093
  • [49] Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations
    Markku Lähteenvuo
    Jari Tiihonen
    [J]. Drugs, 2021, 81 : 1273 - 1284
  • [50] Antipsychotic polypharmacy in the treatment of schizophrenia in China and Japan
    Qiu, Hong
    He, Yong
    Zhang, Yongjing
    He, Minfu
    Liu, Jin
    Chi, Rui
    Si, Tianmei
    Wang, Huaning
    Dong, Wentian
    [J]. AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2018, 52 (12): : 1202 - 1212
12345